NVDA
NVIDIA
-- 147.070 TSLA
Tesla
-- 415.110 ORCL
Oracle
-- 184.220 AAPL
Apple
-- 223.830 ARM
Arm Holdings
-- 179.930 
NEWS
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma
Tuesday, 7th January at 4:05 pm
MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI® Surgical System ("OMNI") in managing primary open-angle glaucoma ("POAG"). This study, in press in the American Journal of Ophthalmology and based on data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), presents compelling evidence supporting the sustained benefits of standalone canaloplasty and trabeculotomy with OMNI, independent of cataract surgery.
This real-world study, led by Nathan M. Radcliffe, MD, of Mount Sinai School of Medicine in New York City, evaluated 230 eyes of 196 patients with POAG through up to 36 months. The results demonstrate clinically and statistically significant reductions in intraocular pressure ("IOP") through up to 36 months postoperatively, with mean reductions ranging from 5.6 to 7.1 mmHg. The study also reports a statistically significant decrease in medication use through 18 months. Eyes with lower baseline IOP experienced medication reduction through 36 months.
Tuesday, 7th January at 4:05 pm
MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI® Surgical System ("OMNI") in managing primary open-angle glaucoma ("POAG"). This study, in press in the American Journal of Ophthalmology and based on data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), presents compelling evidence supporting the sustained benefits of standalone canaloplasty and trabeculotomy with OMNI, independent of cataract surgery.
This real-world study, led by Nathan M. Radcliffe, MD, of Mount Sinai School of Medicine in New York City, evaluated 230 eyes of 196 patients with POAG through up to 36 months. The results demonstrate clinically and statistically significant reductions in intraocular pressure ("IOP") through up to 36 months postoperatively, with mean reductions ranging from 5.6 to 7.1 mmHg. The study also reports a statistically significant decrease in medication use through 18 months. Eyes with lower baseline IOP experienced medication reduction through 36 months.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
6877
Followers
46
Following
74K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day